CN1703246A - 涂指甲及甲周的溶液 - Google Patents
涂指甲及甲周的溶液 Download PDFInfo
- Publication number
- CN1703246A CN1703246A CNA038212145A CN03821214A CN1703246A CN 1703246 A CN1703246 A CN 1703246A CN A038212145 A CNA038212145 A CN A038212145A CN 03821214 A CN03821214 A CN 03821214A CN 1703246 A CN1703246 A CN 1703246A
- Authority
- CN
- China
- Prior art keywords
- solution
- fingernail
- acid
- coated
- carbamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 58
- 210000004905 finger nail Anatomy 0.000 claims description 52
- 235000013877 carbamide Nutrition 0.000 claims description 36
- 239000004202 carbamide Substances 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 27
- 230000003213 activating effect Effects 0.000 claims description 27
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 26
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 17
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 15
- 208000010195 Onychomycosis Diseases 0.000 claims description 15
- 229960003204 amorolfine Drugs 0.000 claims description 15
- 201000005882 tinea unguium Diseases 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 13
- 239000004310 lactic acid Substances 0.000 claims description 12
- 230000000843 anti-fungal effect Effects 0.000 claims description 9
- 229940121375 antifungal agent Drugs 0.000 claims description 8
- 239000006184 cosolvent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 5
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000024386 fungal infectious disease Diseases 0.000 claims description 3
- 150000003672 ureas Chemical group 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 229920001577 copolymer Polymers 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 9
- 210000004906 toe nail Anatomy 0.000 description 9
- 239000010408 film Substances 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001087 glyceryl triacetate Substances 0.000 description 5
- 235000013773 glyceryl triacetate Nutrition 0.000 description 5
- 210000000282 nail Anatomy 0.000 description 5
- 229960002622 triacetin Drugs 0.000 description 5
- -1 alkyl methyl sulfoxide Chemical compound 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- ATUUSOSLBXVJKL-UHFFFAOYSA-N 3-ethylpentanoic acid Chemical compound CCC(CC)CC(O)=O ATUUSOSLBXVJKL-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 206010034016 Paronychia Diseases 0.000 description 2
- 241000029132 Paronychia Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VVMKVFQYONGBPV-MKWAYWHRSA-N (z)-4-butoxy-4-oxobut-2-enoic acid;methoxyethene Chemical compound COC=C.CCCCOC(=O)\C=C/C(O)=O VVMKVFQYONGBPV-MKWAYWHRSA-N 0.000 description 1
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- CXQSCYIVCSCSES-UHFFFAOYSA-N 3-chloropentane Chemical compound CCC(Cl)CC CXQSCYIVCSCSES-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MICRRSRTOYVLMG-UHFFFAOYSA-N 6-hydroxy-4-oxononanoic acid Chemical compound CCCC(O)CC(=O)CCC(O)=O MICRRSRTOYVLMG-UHFFFAOYSA-N 0.000 description 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000011068 Bazex syndrome Diseases 0.000 description 1
- 208000034068 Bazex-Dupré-Christol syndrome Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 206010015146 Erysipeloid Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000030148 Inflammatory linear verrucous epidermal nevus Diseases 0.000 description 1
- 206010022013 Ingrowing nail Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000004204 Larva Migrans Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- 206010028698 Nail dystrophy Diseases 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010048886 Onychoclasis Diseases 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000009163 Sebaceous of Jadassohn Nevus Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000001924 Tungiasis Diseases 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- ANZWPDDIMJTBKY-UHFFFAOYSA-N butyl acetate ethanol ethyl acetate Chemical compound C(C)(=O)OCCCC.C(C)(=O)OCC.C(C)O ANZWPDDIMJTBKY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 201000005473 herpetic whitlow Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 150000002885 octadecanoids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- UBYZGUWQNIEQMH-SBBOJQDXSA-M potassium;(2s,3s,4s,5r)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [K+].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UBYZGUWQNIEQMH-SBBOJQDXSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000037946 swimming pool granuloma Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- LXNOENXQFNYMGT-UHFFFAOYSA-N xi-5-Hydroxydodecanoic acid Chemical compound CCCCCCCC(O)CCCC(O)=O LXNOENXQFNYMGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种起协同作用的助渗透剂在制备皮肤病学或化妆用的涂指甲和甲周溶液中的用途，还涉及由此得到的溶液。
Description
本发明涉及起协同作用的助渗透(pro-penetrating)剂的用途，它们用于制备有皮肤病学或化妆品用途的涂指甲及甲周溶液，本发明还涉及由此得到的溶液。
指甲可以是有不同性质和起因的紊乱、缺乏或病理学客体(Baran R.等人，《指甲疾病及其处理(Diseases of the nails and theirmanagement)》，第3版，2001年)。例如可以提到甲沟炎，其起因可能是细菌、真菌、寄生物或病毒，或者来自皮肤性疾病或全身疾病，或者可能源于药物治疗。真菌病理可能专门位于指甲内部，例如甲真菌病，或者像疱疹或梅毒，会影响身体的其他部位，但也能影响指甲的生理机能。通常指甲真菌感染由皮肤真菌引起，但也可能由霉菌、真菌和酵母菌引起。
现在采用的治疗或者是局部治疗，或者是常规治疗，这两种方法通常结合在一起，以达到最佳的疗效。事实上，为了使治疗有效，看到指甲再生的时间应该很长。另外，真菌病可位于指甲内或甲床内，这就需要活性剂渗透到整个指甲中。
常规治疗经常有不利的副作用，而局部治疗只因难以渗透到指甲中而疗效往往不好。
目前，指甲油或成膜溶液更特别地用于治疗甲真菌病和人类或哺乳动物指甲的类似真菌感染。文献已描述了许多用于预防和治疗这些病症的组合物，这些组合物含有具有抗真菌活性的活性剂，例如像在非水溶性成膜剂中的1-羟基-2-吡啶酮(US 4 957 730)，在含有作为助渗透剂的2-正壬基-1，3-二氧戊环的组合物中的活性剂(WO99/39680)，特比萘芬(US 6 214 360)，伊曲康唑(US 4 267 179)，盐酸阿莫罗芬(EP 0 389 778)或噻康唑(US 5 916 545)。
Marty在《J.Eur.Acad.Dermatol.Venerol.》，4(suppl.1)，S17-S21，(1995)中描述了作为输送载体用于活性剂局部涂敷的指甲油的疗效。这篇文章研究了抗真菌剂盐酸阿莫罗芬的输送问题。如在该文献中所描述，由溶剂、增塑剂和成膜剂组成的指甲油基组合可惜没有使活性剂最佳渗透到指甲中。
因此，证明研制例如涂指甲和甲周溶液这类皮肤病学或化妆品组合物是必要的，它应能使活性剂更好地渗透到指甲中，由此使活性剂的疗效更好，敷用时间缩短。
目前，尿素用作角质溶解剂是已知的事实。尿素还曾是有关它渗透到皮肤中(Wohlrab W.《J.Appl.Cosmetol.》9，1-7(1991年1月，3月))以及与硫醇结合渗透到指甲内的助渗透能力(US 5 696 164)的研究课题。Malhotra G.G.和Zatz J.L.(《J.Pharm.Sciences》，vol 91，2，(2002))描述了含有作为角质溶解剂的尿素和N-(2-巯基丙酰基)甘氨酸的组合，使活性剂能非常好地渗透到指甲中。
还没有现有技术描述过在涂指甲和甲周的溶液中使用酸或乙氧基二甘醇作为助渗透剂。此外，在现有技术描述的组合物中，还没有任何东西能促使本领域的技术人员将尿素与酸或尿素与乙氧基二甘醇混合起来，制备出涂指甲和甲周溶液，其中这种混合物对活性剂渗透到指甲中具有协同作用。
现在，本申请人出乎意料地发现，含有至少尿素和酸，或至少尿素和乙氧基二甘醇的适当助渗透剂混合物的存在，由于它们的协同作用有可能使活性剂在指甲内具有更好的生物利用率。
术语“协同作用”意指其效果高于每一种助渗透剂单独达到的效果之和。
因此，本发明涉及一种起协同作用的助渗透剂的混合物在制备药用或化妆用的涂指甲和甲周溶液中的用途，这些助渗透剂选自尿素、酸和乙氧基二甘醇。因此，本发明的溶液可以含有至少两种这样的助渗透剂，即尿素和酸，或尿素和乙氧基二甘醇，或酸和乙氧基二甘醇，以及这三种试剂的混合物。
术语“涂指甲和甲周溶液”表示涂敷到指甲及其周围的溶液，这种溶液可以是，也可以不是成膜溶液(或指甲油)。
本发明优选地涉及一种助渗透剂混合物在制备药用或化妆用的涂指甲和甲周溶液中的用途，该助渗透剂至少含有尿素和酸。
本发明还涉及一种助渗透剂混合物在制备药用或化妆用的涂指甲和甲周溶液中的用途，该助渗透剂至少含有尿素和乙氧基二甘醇。
一种有协同作用的助渗透剂混合物的用途是更具体地用于制备抗真菌的涂指甲和甲周溶液。
术语“酸”意指“有机酸”，特别是指一元或多元的C1-C18羧酸及其衍生物，例如羟基单羧酸、羟基二羧酸，或游离酸。在本发明的范围内，还可使用由其衍生的内酯、盐和酯。优选地，本发明的酸不是含巯基的氨基酸。
优选地使用C1-C12脂族羧酸，尤其是羟基酸。作为非限制性的实例，可以列举甲酸、2-甲基丁酸、丙酸、2-甲基丙酸、2，2-二甲基丙酸、癸酸、辛酸、己-2-烯酸、庚酸、6-甲基庚酸、3-乙基戊酸、3-氯戊酸、2-羟基丙酸、2-氯-4-羟基己酸、己二酸、十八烷酸、4-氧代戊酸、6-羟基-4-氧代壬酸(6-hydroxy-4-oxononoic acid)、2-酮基丙酸、丙醇二酸、苹果酸、酒石酸、葡糖二酸、柠檬酸、乳酸、羟基乙酸、异柠檬酸、托品酸、5-羟基月桂酸、3-羟基-4-甲氧基扁桃酸或其混合物。
特别地，本发明的溶液可以含有脂族羧酸、乳酸或柠檬酸，优选乳酸。
为了得出一个数量级，本发明使用的涂指甲和甲周溶液，特别是指甲油，优选地以该组合物非挥发性组分重量计包含浓度小于15重量％的尿素，特别地，以该组合物的非挥发性组分重量计包含浓度小于14重量％，优选地，以该组合物的非挥发性组分重量计尿素浓度为7-14重量％，更特别地为9-13重量％。
以该组合物总重量计，酸的重量比例是0.01-15％(重量/重量)，优选地为1-10％，特别地为1-7％。
以该组合物总重量计，乙氧基二甘醇的重量比例是0.01-20％(重量/重量)，优选地为1-10％。
本发明还涉及涂指甲和甲周溶液，该溶液含有助渗透剂混合物，该混合物至少含有尿素和乙氧基二甘醇。
本发明还涉及涂指甲和甲周溶液，该溶液含有助渗透剂混合物，该混合物至少含有尿素和酸，其特征在于它呈非水成膜溶液形式，其特征还在于它含有以该组合物的非挥发性组分重量计15重量％以下的尿素。
术语“非水成膜溶液(指甲油)”意指含有成膜剂的溶液，所述的溶液无添加的水。但是，该溶液含有的残留水量可以不超过该组合物溶剂/助溶剂总浓度的5％。
优选地，这种酸是脂族羧酸，尤其是乳酸。
在本发明的一个实施方案中，如上定义的涂指甲和甲周溶液还含有：
a)至少一种活性剂，
b)有机溶剂/助溶剂混合物，和，
c)一种任选的增塑剂。
溶剂和助溶剂可选自有机溶剂类，并且根据ICH标准(杂质：残留溶剂准则，国际协调会议)，是低毒性的3级溶剂，例如乙醇、乙醇100或乙醇95、丙酮、乙酸甲酯、乙酸乙酯、乙酸丁酯，如二甲基亚砜之类的烷基甲基亚砜、2-丙醇、甲基异丁基酮、1-丁醇、二氯甲烷或其混合物。
在这些上述溶剂/助溶剂中，优选地使用挥发性的有机溶剂/助溶剂，更优选地使用由乙醇、乙酸乙酯和乙酸丁酯组成的混合物。
溶剂/助溶剂的优选使用浓度是以该组合物总重量计分别为30-90重量％和0-30重量％，更优选地以该组合物总重量计分别为35-60重量％和10-25重量％。
为了制备本发明的指甲油组合物，该组合物要求存在成膜剂，所述成膜剂有利地是水不溶性的，并选自：
-聚乙烯基甲醚与苹果酸的单烷基酯的共聚物，如ISP公司以商品名Gantrez ES 425销售的聚乙烯基甲醚与苹果酸的丁酯的共聚物(PVM/MA的丁酯共聚物)，
-丙烯酸与甲基丙烯酸的酯的共聚物，其中由丙烯酸衍生的季铵基团含量很低，例如Rhm Pharma公司以商品名Eudragit RL 100销售的丙烯酸酯和甲基丙烯酸铵的共聚物(丙烯酸酯/甲基丙烯酸铵共聚物)，
-或纤维素衍生物，例如Aqualon公司销售的硝基纤维素或乙基纤维素，
-聚氨酯衍生物，例如Noveon公司销售的Avalures。
上述成膜剂的优选使用浓度是以该组合物总重量计0.01-20重量％。
增塑剂的浓度优选地是以该组合物总重量计0.001-10.00重量％，更特别地为0.01-5.00重量％。在这些增塑剂中，不受所列限制使用诸如邻苯二甲酸酯、三乙酸酯、柠檬酸酯或其混合物之类的化合物。
作为非限制性实例，这种活性剂可以是抗生素、抗菌剂、甾体消炎剂、非甾体消炎剂、抗寄生虫剂、抗病毒剂、免疫抑制剂、核受体调节剂、抗真菌剂或其混合物。
在抗生素中，可以提到例如氟喹诺酮类、利福霉素、交沙霉素、磺胺嘧啶、维及尼霉素、夫西地酸或其混合物。
在抗菌剂中，可以提到例如过氧化苯甲酰。
在甾体消炎剂中，可以提到例如丁氯倍他松、氢化可的松、醋酸氟轻松、地奈德、倍他米松、地塞米松或其混合物。
在非甾体消炎剂中，可以提到吲哚衍生物、芳基羧酸衍生物、昔康类(oxicams)、吡唑衍生物或其混合物。
在抗寄生虫剂中，可以提到例如克罗他米通。
在抗病毒剂中，可以提到例如阿糖腺苷。
在免疫抑制剂中，可以提到例如氨甲喋呤、环孢霉素、他克莫司或其混合物。
在核受体调节剂中，可以提到例如类视色素、或维生素D及其同功异质体或其混合物。
在抗真菌剂中，可以提到例如属咪唑类的益康唑、酮康唑或密康唑；吡咯化合物，例如伊曲康唑或克霉唑之类；双三唑化合物，例如氟康唑；烯丙基胺族化合物，例如特比萘芬；吡啶酮类，例如环吡酮胺；吗啉类，例如阿莫罗芬及其盐；多烯化合物，例如两性霉素B；灰黄霉素，或其混合物。
该活性剂优选地选自抗真菌剂。
因此，本发明的涂指甲和甲周溶液优选地是抗真菌溶液，特别地，它们含有阿莫罗芬或它的盐中的一种。
以该组合物总重量计，活性剂的优选浓度是0.001-20重量％。
本发明的涂指甲和甲周溶液还可以含有在化妆品或药物领域中通常使用的添加剂，如多价螯合剂、润湿剂、粘合剂、涂铺剂、抗氧化剂、防晒剂、防腐剂、填料、电解质、保湿剂、颜料、染料，通常的无机或有机碱或酸类、精油、化妆活性剂、保湿液、维生素、必需脂肪酸或神经鞘脂。当然，本领域技术人员会谨慎选择这种或这些任选的补充化合物和/或它(们)的量，以便本发明组合物的有利性质不会或基本不会受到损害。
本发明的涂指甲和甲周溶液特别适合于下述的皮肤病学治疗领域：甲癣、chloronychia、甲沟炎、类丹毒、脆甲症、淋病、游泳池肉芽肿、蠕虫蚴行症、麻风、羊痘疮结(orf nodule)、乳牛结(milkers′nodules)、疱疹性瘭疽、急性细菌性甲周炎、慢性甲周炎、孢子丝菌病、梅毒、疣状皮肤结核、土拉菌病、潜蚤病、甲周疣和甲下疣、带状疮疹、20指甲营养不良(trachyonychia)，以及影响指甲的皮肤病，如牛皮癣、脓疱性银屑病、斑秃、角化不全性银屑病(parakeratosispustulosa)、接触性职业皮肤病、瑞特综合症、牛皮癣状肢端皮炎psoriasiform acral dermatitis)、扁平苔藓、指甲中特发性萎缩、光泽苔藓、条纹状苔藓、炎症性线状疣状表皮痣(ILVEN)、脱发、天疱疮、大疱性类天疱疮、后天性大疱性表皮松解症、毛囊角化症、毛发红糠疹、掌跖角化病、接触性皮炎、多形性红癍、疥疮、Bazex综合征、全身性硬皮病、全身性红斑狼疮、慢性红斑狼疮、皮肌炎。
本发明的涂指甲和甲周溶液更特别适合于治疗和预防甲癣。
本发明的目的还涉及如上所述的涂指甲和甲周溶液在制备意欲治疗诸如甲癣之类真菌病药品中的用途。
本发明的涂指甲和甲周溶液还应用于化妆品领域，特别用于治疗指甲不齐、匙状甲、博氏线、纵脊、嵌甲。
下面的实施例能说明本发明，而不限制其范围。在这些配方实施例中(实施例1-9)，除非另外说明，这些组分的量都是以该组合物的总重量计以重量％表示的。
还描述了一些说明本发明组合物中活性剂释放-渗透作用的实施例。
实施例1：
| 组分 | ％ |
| 乙醇 | 43.85 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 尿素 | 2.50 |
| 乳酸 | 4.25 |
| 盐酸阿莫罗芬 | 6.40 |
| PVM/MA丁酯共聚物 | 20.00 |
这种溶液可涂于足部趾甲，在9个月内每周一次，用于治疗甲癣。
实施例2：
| 组分 | ％ |
| 乙醇 | 51.90 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 三乙酸甘油酯 | 1.20 |
| 尿素 | 2.5 |
| 乙氧基二甘醇 | 5.00 |
| 盐酸阿莫罗芬 | 6.40 |
| 丙烯酸酯/甲基丙烯酸铵共聚物 | 10.00 |
该溶液可涂于指甲，在9个月内每周一次，用于治疗甲癣。
实施例3：
| 组分 | ％ |
| 乙醇 | 53.85 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 尿素 | 2.50 |
| 乳酸 | 4.25 |
| 密康唑 | 6.40 |
| 丙烯酸酯/甲基丙烯酸铵共聚物 | 10.00 |
该溶液可涂于指甲，在1-2个月内每天两次，用于治疗急性细菌性甲周炎。
实施例4：
| 组分 | ％ |
| 乙醇 | 43.10 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 尿素 | 2.50 |
| 乙氧基二甘醇 | 5.00 |
| 盐酸阿莫罗芬 | 6.40 |
| PVM/MA丁酯共聚物 | 20.00 |
该溶液可涂于手指甲，在6个月内一周一次，用于治疗甲癣。
实施例5：
| 组分 | ％ |
| 乙醇 | 48.10 |
| 丙酮 | 28.00 |
| 尿素 | 2.50 |
| 乙氧基二甘醇 | 5.00 |
| 盐酸阿莫罗芬 | 6.40 |
| 丙烯酸酯/甲基丙烯酸铵共聚物 | 10.00 |
该溶液可涂于足部趾甲，在9个月内每周一次，用于治疗甲癣。
实施例6：
| 组分 | ％ |
| 乙醇 | 45.65 |
| 丙酮 | 20.00 |
| 三乙酸甘油酯 | 1.20 |
| 尿素 | 2.50 |
| 乳酸 | 4.25 |
| 盐酸阿莫罗芬 | 6.40 |
| PVM/MA丁酯共聚物 | 20.00 |
该溶液可涂于指甲，在6-8个月内每周一次，用于治疗甲癣。
实施例7：
| 组分 | ％ |
| 二氯甲烷 | 52.65 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 三乙酸甘油酯 | 1.20 |
| 尿素 | 2.50 |
| 柠檬酸 | 4.25 |
| 盐酸阿莫罗芬 | 6.40 |
| 丙烯酸酯/甲基丙烯酸铵共聚物 | 10.00 |
该溶液可涂于足部趾甲，在9个月内每周二次，用于治疗甲癣。
实施例8：
| 组分 | ％ |
| 二氯甲烷 | 66.85 |
| 丙酮 | 20.00 |
| 甘油 | 5.00 |
| 尿素 | 2.50 |
| 乳酸 | 4.25 |
| 盐酸阿莫罗芬 | 8.00 |
该溶液可涂于足部趾甲，在6-12个月内每周一次，用于治疗甲癣。
实施例9：
| 组分 | ％ |
| 乙醇 | 37.39 |
| 乙酸乙酯 | 17.00 |
| 乙酸丁酯 | 6.00 |
| 尿素 | 2.50 |
| 乳酸 | 4.25 |
| PVM/MA丁酯共聚物 | 20.00 |
| 盐酸阿莫罗芬 | 1.2.86 |
该溶液可涂于足部趾甲，在6-12个月内每周一次，用于治疗甲癣。
实施例10：物理和化学稳定性
将本发明组合物置于各种温度下，进行随着时间流逝的物理评定(该组合物的颜色和物理结构)。
| 稳定性实施例1 | 40℃：3个月RAS* |
| 4℃：3个月RAS | |
| 室温：3个月RAS |
*RAS：该薄膜没有浑浊和破裂，没有发黄，也没有再结晶。
化学稳定性
在室温和40℃下，在时间为0和2个月时通过测定这种活性剂来评定所述活性剂的降解作用。
| 稳定性实施例1 | T0 99.10％ |
| 室温2个月：100.3％ | |
| 40℃2个月：99.2％ |
在进行的试验中稳定性检测结果表明，从颜色和物理结构来看，本发明组合物在所有试验温度下随着时间变化都是稳定的。
使用的活性剂没有显示出任何重结晶迹象，并且在所有温度下随着时间变化也都是稳定的。
实施例11：释放-渗透作用
方法
使用扩散池，更具体地Frantz(Pittrof F等人，《Clin.Exp.Dermatol.》17(suppll)：26-28，(1992))，在猪趾甲上进行活性剂释放-渗透作用的研究。
根据本发明，将活性剂加入指甲油中。
每天往1cm2趾甲表面积上涂敷10ul待试验指甲油(含有放射性同位素标记的活性剂)，连续涂3天。
然后，通过使用闪烁计数器测定其放射性来评定趾甲中的活性剂。
这个试验在6个池中并行地进行，参比指甲油作为对照。这种参比指甲油(参比)不含任何助渗透剂，它由55.20％乙醇、17.20％乙酸乙酯、5.70％乙酸丁酯、1.20％三乙酸甘油酯、14.30％Eudragit R1 100、6.40％盐酸阿莫罗芬组成。
对照指甲油仅含有一种助渗透剂，该助渗透剂是尿素或者乳酸或者乙氧基二甘醇。
结果
| 组合物 | 参照e | 对照1 | 对照2 | 对照3 | 实施例1 | 实施例4 |
| 乙醇乙酸乙酯乙酸丁酯 | 55.2017.205.70 | 44.4017.006.00 | 54.4017.006.00 | 54.4017.006.00 | 43.8517.006.00 | 43.1017.006.00 |
| 三乙酸甘油酯 | 1.20 | 1.20 | - | - | - | - |
| 乙氧基二甘醇尿素乳酸 | 5.00-- | -2.50- | --4.25 | -2.504.25 | 5.002.50- | |
| Eudragit R1 100Gantrez ES 425 | 14.30- | -20.00 | 10.00- | 10.00- | 20.00 | 20.00 |
| 盐酸阿莫罗芬 | 6.40 | 6.40 | 6.40 | 6.40 | 6.40 | 6.40 |
| 释放-渗透增加 | 1 | 1 | 1 | 1 | 3.06 | 2.16 |
与参比指甲油相比，本发明指甲油能明显提高活性剂渗透到指甲中(实施例4为2倍以上，实施例1为3倍以上)，而单独试验的各种助渗透剂(对照组合物)根本没有提高活性剂渗透到猪趾甲中(与参比指甲油相比，释放-渗透差异不明显)。
这些结果明确表明，本发明的尿素和乙氧基二甘醇，或尿素与酸，助渗透剂组合能以协同方式提高活性剂渗透到指甲中。
Claims (12)
1、一种起协同作用的助渗透剂的混合物在制备药用或化妆用的涂指甲和甲周溶液中的用途，所述助渗透剂选自尿素、酸和乙氧基二甘醇。
2、根据权利要求1的用途，其特征在于所述溶液是成膜溶液或指甲油。
3、根据权利要求1或2的用途，其特征在于使用至少含有尿素和乙氧基二甘醇的助渗透剂混合物。
4、根据权利要求1-3中任一项的用途，其特征在于使用至少含有尿素和酸的助渗透剂混合物。
5、涂指甲和甲周溶液，该溶液含有助渗透剂混合物，该混合物至少含有尿素和乙氧基二甘醇。
6、涂指甲和甲周溶液，该溶液含有助渗透剂混合物，该混合物至少含有尿素和酸，其特征在于它呈非水成膜溶液形式，其特征还在于它含有以该组合物非挥发性组分总重量计15重量％以下量的尿素。
7、根据权利要求6的涂指甲和甲周溶液，其特征在于所述酸是脂族羧酸。
8、根据权利要求7的涂指甲和甲周溶液，其特征在于脂族羧酸是乳酸。
9、根据权利要求5-8中任一项的涂指甲和甲周溶液，其特征在于它还含有：
a)至少一种活性剂，
b)有机溶剂/助溶剂混合物，和
c)一种任选的增塑剂。
10、根据权利要求9的涂指甲和甲周溶液，其特征在于所述活性剂是抗真菌剂。
11、根据权利要求10的涂指甲和甲周溶液，其特征在于抗真菌剂选自阿莫罗芬或其中一种盐。
12、根据上述权利要求中任一项的涂指甲和甲周溶液在制备治疗诸如甲癣之类真菌病药品中的用途。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0211023 | 2002-09-05 | ||
| FR0211023A FR2844197B1 (fr) | 2002-09-05 | 2002-09-05 | Solution pour application ungueale et peri-ungeale |
| US60/411,349 | 2002-09-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101641308A Division CN101632627B (zh) | 2002-09-05 | 2003-09-01 | 涂指甲及甲周的溶液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1703246A true CN1703246A (zh) | 2005-11-30 |
| CN100542610C CN100542610C (zh) | 2009-09-23 |
Family
ID=31725870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101641308A Expired - Fee Related CN101632627B (zh) | 2002-09-05 | 2003-09-01 | 涂指甲及甲周的溶液 |
| CNB038212145A Expired - Fee Related CN100542610C (zh) | 2002-09-05 | 2003-09-01 | 涂指甲及甲周的溶液及其在制备治疗真菌病药品中的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101641308A Expired - Fee Related CN101632627B (zh) | 2002-09-05 | 2003-09-01 | 涂指甲及甲周的溶液 |
Country Status (3)
| Country | Link |
|---|---|
| CN (2) | CN101632627B (zh) |
| AR (1) | AR041146A1 (zh) |
| FR (1) | FR2844197B1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102844026A (zh) * | 2010-02-26 | 2012-12-26 | Lrc产品有限公司 | 真菌甲治疗组合物 |
| CN103796682A (zh) * | 2011-06-22 | 2014-05-14 | Urgo实验室 | 成膜组合物及其在治疗疱疹中的应用 |
| CN105106179A (zh) * | 2015-08-28 | 2015-12-02 | 江苏福邦药业有限公司 | 一种盐酸阿莫罗芬搽剂的制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007102241A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE325667B (zh) * | 1968-03-06 | 1970-07-06 | Medisan Ab | |
| JPS58150509A (ja) * | 1982-03-03 | 1983-09-07 | Taisho Pharmaceut Co Ltd | 白癬症治療剤 |
| DE3210138A1 (de) * | 1982-03-19 | 1983-09-22 | Röhm Pharma GmbH, 6100 Darmstadt | Antimykotische, therapeutische zubereitungen auf creme- und salbenbasis |
| JPS60174716A (ja) * | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
| SE462139B (sv) * | 1986-02-04 | 1990-05-14 | Sven Moberg | Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem |
| FR2613227B1 (fr) * | 1987-04-01 | 1990-12-28 | Oreal | Compositions pharmaceutiques a base de nitrate de miconazole ou de nitrate d'econazole dans le traitement des infections fongiques des ongles |
| CN1032116C (zh) * | 1989-06-23 | 1996-06-26 | 铁汉 | 病甲剥脱剂的制造方法 |
| CN1063820A (zh) * | 1991-01-30 | 1992-08-26 | 樊芝芹 | 灰指甲溶解膏的制造方法 |
| FR2673537B1 (fr) * | 1991-03-08 | 1993-06-11 | Oreal | Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes. |
| DE4137544C2 (de) * | 1991-11-12 | 1998-07-30 | Kramer Axel | Antimikrobielle Wirkstoffkombination auf der Basis von Sauerstoff abspaltenden Verbindungen |
| NL9401095A (nl) * | 1994-06-30 | 1996-02-01 | Drs Erwin Philip Balthazar Pli | Kosmetisch preparaat voor de verbetering van de eigenschappen van nagels, werkwijze voor het aanbrengen hiervan en toepassing hiervan. |
| US5696164A (en) * | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| FR2737406B1 (fr) * | 1995-08-04 | 1997-10-24 | Sederma Sa | Gel a activite physique pour produits cosmetiques |
| US6162419A (en) * | 1996-11-26 | 2000-12-19 | Nicholas V. Perricone | Stabilized ascorbyl compositions |
| US5993790A (en) * | 1997-08-04 | 1999-11-30 | Pedinol Pharmacal Inc. | Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections |
| US6740326B1 (en) * | 1998-09-10 | 2004-05-25 | Bioequal Ag | Topical nail care compositions |
| ATE320250T1 (de) * | 2000-01-03 | 2006-04-15 | Karl Kraemer | Zubereitungen zur atraumatischen nagelentfernung |
-
2002
- 2002-09-05 FR FR0211023A patent/FR2844197B1/fr not_active Expired - Fee Related
-
2003
- 2003-09-01 CN CN2009101641308A patent/CN101632627B/zh not_active Expired - Fee Related
- 2003-09-01 CN CNB038212145A patent/CN100542610C/zh not_active Expired - Fee Related
- 2003-09-04 AR ARP030103207A patent/AR041146A1/es unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102844026A (zh) * | 2010-02-26 | 2012-12-26 | Lrc产品有限公司 | 真菌甲治疗组合物 |
| CN103796682A (zh) * | 2011-06-22 | 2014-05-14 | Urgo实验室 | 成膜组合物及其在治疗疱疹中的应用 |
| CN105106179A (zh) * | 2015-08-28 | 2015-12-02 | 江苏福邦药业有限公司 | 一种盐酸阿莫罗芬搽剂的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101632627A (zh) | 2010-01-27 |
| CN101632627B (zh) | 2013-01-16 |
| CN100542610C (zh) | 2009-09-23 |
| AR041146A1 (es) | 2005-05-04 |
| FR2844197B1 (fr) | 2006-06-23 |
| FR2844197A1 (fr) | 2004-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2329063C2 (ru) | Раствор для применения в области ногтей и околоногтевого пространства | |
| US6224887B1 (en) | Antifungal nail lacquer and method using same | |
| CN1191060C (zh) | 输送前列腺素e1的表皮给药组合物 | |
| FR2892023A1 (fr) | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale | |
| CA2623031C (en) | Antifungal composition | |
| JPH069342A (ja) | 爪真菌症治療のためのネイルエナメル | |
| PL205865B1 (pl) | Plaster zawierający warstwę przeznaczoną do pozostawania w bezpośrednim kontakcie z paznokciem i ewentualnie z otaczającą skórą oraz zastosowanie wymienionej warstwy do wytwarzania plastra | |
| CN1703246A (zh) | 涂指甲及甲周的溶液 | |
| US7615238B2 (en) | Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole | |
| US8257688B2 (en) | Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1085390 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1085390 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090923 Termination date: 20150901 |
|
| EXPY | Termination of patent right or utility model |